We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: Be Explicit When Interpreting Noncompliance to Protect Clinical Trials
Expert: Be Explicit When Interpreting Noncompliance to Protect Clinical Trials
Institutional review boards that fail to write explicit policies defining clinical trial noncompliance are putting themselves and their research sites at risk, an industry expert says.